Research graph
References from Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation. Local targets link to admitted publications; unresolved targets remain external evidence.
Melanoma: from incurable beast to a curable bet. The success of immunotherapy
10.3389/fonc.2015.00152 · 2015 · External reference
Targeting immune checkpoints in hematologic malignancies
10.1124/pr.116.012682 · 2016 · External reference
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
10.2147/ott.s111209 · 2016 · External reference
Advances in treatment of metastatic renal cell carcinoma
10.1097/mou.0000000000000319 · 2016 · External reference
The emerging role of immunotherapy in colorectal cancer
10.21037/atm.2016.08.29 · 2016 · External reference
Combining radiotherapy and cancer immunotherapy: a paradigm shift
10.1093/jnci/djs629 · 2013 · External reference
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
10.1007/s00262-013-1474-y · 2014 · External reference
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment
2015 · External reference
New clinical advances in immunotherapy for the treatment of solid tumours
10.1111/imm.12459 · 2015 · External reference
Therapeutic cancer vaccines
10.1172/jci80009 · 2015 · External reference
HLA ligandome tumor antigen discovery for personalized vaccine approach
10.1586/14760584.2013.836911 · 2013 · External reference
Immunocytokines for cancer treatment: past, present and future
10.1016/j.coi.2016.03.006 · 2016 · External reference
CAR-modified T-cell therapy for cancer: an updated review
10.3109/21691401.2015.1052465 · 2016 · External reference
Bispecific antibody platforms for cancer immunotherapy
10.1016/j.critrevonc.2014.08.003 · 2014 · External reference
Tumor-antigen-binding bispecific antibodies for cancer treatment
10.1053/j.seminoncol.2014.08.004 · 2014 · External reference
Application potential of toll-like receptors in cancer immunotherapy: systematic review
10.1097/md.0000000000003951 · 2016 · External reference
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
10.1371/journal.pone.0090353 · 2014 · External reference
Selection and expansion of natural killer cells for NK cell-based immunotherapy
10.1007/s00262-016-1792-y · 2016 · External reference
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy
10.1016/j.coph.2015.05.008 · 2015 · External reference
The basic principles of chimeric antigen receptor design
10.1158/2159-8290.cd-12-0548 · 2013 · External reference
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
10.1038/316354a0 · 1985 · External reference
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer
10.4161/21645515.2014.983857 · 2014 · External reference
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer
10.1007/s00262-015-1781-6 · 2016 · External reference
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS
10.1158/1078-0432.ccr-14-0202 · 2015 · External reference
Personalized cancer vaccines: targeting the cancer mutanome
2016 · External reference
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
10.1186/1471-2407-14-748 · 2014 · External reference
Antitumor dendritic cell-based vaccines: lessons from 20years of clinical trials and future perspectives
10.1016/j.trsl.2015.07.008 · 2016 · External reference
High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features
10.3109/15476911003657414 · 2010 · External reference
Selected anti-tumor vaccines merit a place in multimodal tumor therapies
10.3389/fonc.2012.00132 · 2012 · External reference
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
10.1002/pros.20941 · 2009 · External reference
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
10.1002/ijc.26365 · 2012 · External reference
Tolerance and immune suppression in the tumor microenvironment
10.1016/j.cellimm.2015.09.011 · 2016 · External reference
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?
10.1089/cbr.2012.1220 · 2012 · External reference
IL-2: the first effective immunotherapy for human cancer
10.4049/jimmunol.1490019 · 2014 · External reference
The toxicology of interleukin-12: a review
10.1177/019262339902700112 · 1999 · External reference
IL-12 deaths: explanation and a puzzle
10.1126/science.270.5238.908a · 1995 · External reference
The immunocytokine NHS-IL12 as a potential cancer therapeutic
10.18632/oncotarget.1853 · 2014 · External reference
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
10.1080/2162402x.2015.1021541 · 2015 · External reference
Combination of radiotherapy with the immunocytokine L19-IL2: additive effect in a NK cell dependent tumour model
10.1016/j.radonc.2015.06.019 · 2015 · External reference
Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation
10.1080/2162402x.2015.1014760 · 2015 · External reference
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
10.1073/pnas.1002569107 · 2012 · External reference
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25
10.1073/pnas.0909384107 · 2010 · External reference
Tolerance, not immunity, crucially depends on IL-2
10.1038/nri1435 · 2004 · External reference
Non-targeted effects of radiation exposure: recent advances and implications
10.1093/rpd/ncv167 · 2015 · External reference
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
10.1158/0008-5472.can-04-0073 · 2004 · External reference
Immunogenic cell death in cancer and infectious disease
10.1038/nri.2016.107 · 2016 · External reference
Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells
10.3109/1547691x.2014.880533 · 2014 · External reference
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
10.1084/jem.20050915 · 2005 · External reference
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
10.1038/nm1622 · 2007 · External reference
Radiation induces an antitumour immune response to mouse melanoma
10.3109/09553000903242099 · 2009 · External reference
Consensus guidelines for the detection of immunogenic cell death
10.4161/21624011.2014.955691 · 2014 · External reference
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
10.1016/j.vaccine.2015.05.105 · 2015 · External reference
Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner
10.1038/cddis.2015.129 · 2015 · External reference
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
10.1084/jem.20052494 · 2006 · External reference
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015 · External reference
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
10.1038/nature14292 · 2015 · External reference
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
2002 · External reference
Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy
10.1016/j.ccr.2013.09.014 · 2013 · External reference
A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial)
10.1186/s12885-015-2006-2 · 2015 · External reference
The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation
2016 · External reference
Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function
10.1111/cei.12344 · 2015 · External reference
Radiobiological mechanisms of anti-inflammatory radiotherapy
10.1016/s0167-8140(99)00066-3 · 1999 · External reference
Modulation of inflammation by low and high doses of ionizing radiation: implications for benign and malign diseases
10.1016/j.canlet.2015.04.010 · 2015 · External reference
Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing gamma-irradiation
10.1158/0008-5472.can-15-3451 · 2016 · External reference
Liquid biopsy can distinguish recurrent glioblastomas from pseudoprogression and radiation necrosis after concurrent radiochemotherapy
10.1227/01.neu.0000489788.06793.47 · 2016 · External reference
Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry
10.3390/ijms17081316 · 2016 · External reference
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
10.1182/blood-2014-12-580068 · 2015 · External reference
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
10.1200/jco.2014.56.3247 · 2014 · External reference
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
10.1200/jco.2010.32.7270 · 2011 · External reference
Engineered T cells: the promise and challenges of cancer immunotherapy
10.1038/nrc.2016.97 · 2016 · External reference
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
10.18632/oncotarget.2767 · 2015 · External reference
CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
10.1007/s00262-012-1202-z · 2012 · External reference
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
10.1038/nrclinonc.2016.25 · 2016 · External reference
Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma
10.1200/jco.2016.66.7220 · 2016 · External reference
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
10.4049/jimmunol.174.12.7516 · 2005 · External reference
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells
10.4049/jimmunol.181.5.3099 · 2008 · External reference
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
10.1172/jci67313 · 2014 · External reference
NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance
10.1667/rr1472.1 · 2009 · External reference
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts
10.1158/1078-0432.ccr-06-0441 · 2006 · External reference
TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
10.4161/onci.26770 · 2013 · External reference
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
10.3389/fonc.2012.00104 · 2012 · External reference
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
10.1126/scitranslmed.aaa4306 · 2015 · External reference
GM-CSF gene-transduced tumor vaccines
10.1016/j.ymthe.2005.02.012 · 2005 · External reference
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
10.1158/2326-6066.cir-14-0069 · 2014 · External reference
Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer
10.1158/1535-7163.mct-14-1015 · 2015 · External reference
The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
10.1080/2162402x.2015.1016709 · 2015 · External reference
Combination of radiotherapy and vaccination overcome checkpoint blockade resistance
10.18632/oncotarget.9915 · 2016 · External reference
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
10.1126/science.aad1329 · 2015 · External reference
Using DNA, radiation therapy gets personal
10.1126/science.353.6306.1348 · 2016 · External reference
Th1 cytokine-based immunotherapy for cancer
10.1016/s1499-3872(14)60305-2 · 2014 · External reference
The IL-2 cytokine family in cancer immunotherapy
10.1016/j.cytogfr.2014.07.018 · 2014 · External reference
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production
10.4049/jimmunol.153.4.1697 · 1994 · External reference
Interleukin-12 and the regulation of innate resistance and adaptive immunity
10.1038/nri1001 · 2003 · External reference
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
10.1172/jci58814 · 2011 · External reference
Interleukin 12: still a promising candidate for tumor immunotherapy?
10.1007/s00262-014-1523-1 · 2014 · External reference
In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments
10.1158/0008-5472.can-15-2644 · 2016 · External reference
Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects
10.1158/1078-0432.ccr-14-2676 · 2015 · External reference
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
10.1186/s12967-015-0397-0 · 2015 · External reference
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
10.1182/blood.v99.5.1659 · 2002 · External reference
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature
10.1016/j.leukres.2015.04.005 · 2015 · External reference
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
10.1182/blood-2008-05-160747 · 2009 · External reference
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
10.1158/1078-0432.ccr-08-0157 · 2008 · External reference
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
10.18632/oncotarget.6055 · 2015 · External reference
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
10.1016/j.ejca.2010.07.033 · 2010 · External reference
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
10.1007/s00262-015-1704-6 · 2015 · External reference
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses
10.1158/2326-6066.cir-13-0206 · 2014 · External reference
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma
10.1158/1078-0432.ccr-11-1203 · 2011 · External reference
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF
10.1038/jid.2012.376 · 2013 · External reference
Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
10.1089/15368590152740707 · 2001 · External reference
A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity
10.1158/1078-0432.ccr-10-2921 · 2011 · External reference
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
10.1016/j.ejca.2012.07.015 · 2013 · External reference
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
10.1186/1479-5876-11-5 · 2013 · External reference
Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma
10.1371/journal.pone.0129954 · 2015 · External reference
Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models
10.1007/s00262-016-1863-0 · 2016 · External reference
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
10.1056/nejmoa1414428 · 2015 · External reference
Immunotherapy for non-small-cell lung cancer: the past 10 years
2015 · External reference
Immunotherapy of ovarian cancer: the role of checkpoint inhibitors
10.1155/2015/191832 · 2015 · External reference
Immune checkpoint inhibitors: new insights and current place in cancer therapy
10.1002/phar.1643 · 2015 · External reference
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
10.1158/0008-5472.can-12-2606 · 2013 · External reference
Radiation as an immunological adjuvant: current evidence on dose and fractionation
10.3389/fonc.2012.00153 · 2012 · External reference
Awakening the immune system with radiation: optimal dose and fractionation
10.1016/j.canlet.2015.03.024 · 2015 · External reference
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial
10.1016/j.ejca.2016.09.013 · 2016 · External reference
